Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus. A 52-week randomised, double-blind, active- and placebo-controlled trial
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 17 Apr 2018
At a glance
- Drugs Semaglutide (Primary) ; Liraglutide; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PIONEER 4
- Sponsors Novo Nordisk
- 17 Apr 2018 This trial has been completed in Croatia (End date: 2018-03-30).
- 14 Apr 2018 This trial has been completed in Croatia (End date: 2018-03-30) .
- 27 Mar 2018 This trial has been completed in Germany.